Clinigen Group Plc acquires IDIS Group Holdings for £225m

Deal typeTransaction Services
IndustryLife Sciences

Clinigen Group plc is an AIM-listed speciality global pharmaceutical group, with a market capitalisation in excess of £500 million.          

The BDO Transaction Services team in Birmingham provided Investigating Accountant services to Clinigen in connection with their acquisition of the Idis Group. Headquartered in Weybridge, UK, Idis supplies unlicensed medicines through Managed Access Programs and on-demand through its General Access Division. The transaction was funded via a vendor placing (raising gross proceeds of £135 million) and by £104 million drawn down under new debt facilities. The acquisition gives the enlarged group a market leading position in the $5bn+ unlicensed medicine supply sector and strengthens its leading position in the $2bn clinical trial supply market.       

“The BDO transaction team have been valued advisers to Clinigen since our listing on AIM in September 2012, and have assisted on a number of our subsequent product acquisitions. The acquisition of the Idis Group satisfies a number of our key strategic goals and throughout the transaction the BDO team were proactive, flexible and showed great commitment to deliver in full and meet challenging deadlines. They offered valuable advice and I would not hesitate to recommend them.”

Robin Sibson, Chief Finance Officer, Clinigen Group PLC